Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson’s disease. Positive results were reported in Phase II clinical trials in humans but it did not prove itself to be more effective than a placebo during Phase III trials and so was discontinued in May 2013.
This page contains content from the copyrighted Wikipedia article "Preladenant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
